New and existing pharmacotherapeutic options for persistent asthma and COPD

Z. Diamant*, S. Tarasevych, G. W. Clarke

*Corresponding author for this work

    Research output: Contribution to journalReview articleAcademicpeer-review

    4 Citations (Scopus)

    Abstract

    Asthma and COPD are chronic inflammatory airway disorders with systemic manifestations. The two diseases have different airway inflammation, features of airway remodelling with subsequent pathophysiology and clinical presentation. The international management guidelines recommend stepwise pharmacotherapy depending on disease control and/or disease stage, comprising relievers and overall uniform controller treatment, despite the heterogeneity across the conditions and treatment response. Despite effective medications per se, still too many patients remain uncontrolled and no treatment can definitely cure either of the conditions. This overview includes currently recommended pharmacotherapeutic options with novel and future treatment targets.

    Original languageEnglish
    Pages (from-to)486-499
    Number of pages14
    JournalNetherlands Journal of Medicine
    Volume69
    Issue number11
    Publication statusPublished - 2011

    Keywords

    • Asthma
    • COPD
    • pharmacotherapy
    • anticholinergics
    • beta2 agonists
    • xanthines
    • inhaled corticosteroids
    • leukotriene modulators
    • PDE-inhibitors
    • anti-IgE
    • anti-cytokines
    • OBSTRUCTIVE PULMONARY-DISEASE
    • ADD-ON MONTELUKAST
    • RANDOMIZED CLINICAL-TRIALS
    • SMOOTH-MUSCLE-CELLS
    • TO-MODERATE ASTHMA
    • LUNG-FUNCTION
    • BECLOMETHASONE DIPROPIONATE
    • AIRWAY HYPERRESPONSIVENESS
    • INHALED CORTICOSTEROIDS
    • PHOSPHODIESTERASE INHIBITORS

    Cite this